ONESOURCEPharmaceuticals
OneSource Specialty Pharma Inc — Cash Flow Statement
₹1473.30
+8.47%
OneSource Specialty Pharma Inc Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Free Cash Flow | -196.00 Cr | -170.98 Cr | -206.76 Cr |
| Repayment Of Debt | -631.04 Cr | -925.92 Cr | -488.86 Cr |
| Issuance Of Debt | 345.05 Cr | 645.22 Cr | 156.22 Cr |
| Issuance Of Capital Stock | 875.52 Cr | 0.00 | 564.76 Cr |
| Capital Expenditure | -128.15 Cr | -63.77 Cr | -43.99 Cr |
| End Cash Position | 165.36 Cr | 22.26 Cr | 9.47 Cr |
| Other Cash Adjustment Outside Changein Cash | 0.02 Cr | — | — |
| Beginning Cash Position | 22.26 Cr | 9.47 Cr | 121.75 Cr |
| Changes In Cash | 143.07 Cr | 12.79 Cr | -112.28 Cr |
| Financing Cash Flow | 412.01 Cr | -390.54 Cr | 118.32 Cr |
| Interest Paid Cff | -156.54 Cr | -103.28 Cr | -105.29 Cr |
| Net Common Stock Issuance | 875.52 Cr | 0.00 | 564.76 Cr |
| Common Stock Issuance | 875.52 Cr | 0.00 | 564.76 Cr |
| Net Issuance Payments Of Debt | -285.99 Cr | -280.70 Cr | -332.64 Cr |
| Net Short Term Debt Issuance | 95.05 Cr | -130.34 Cr | 103.37 Cr |
| Short Term Debt Issuance | 95.05 Cr | 352.50 Cr | 103.37 Cr |
| Net Long Term Debt Issuance | -381.04 Cr | -150.36 Cr | -436.01 Cr |
| Long Term Debt Payments | -631.04 Cr | -795.58 Cr | -488.86 Cr |
| Long Term Debt Issuance | 250.00 Cr | 645.22 Cr | 52.85 Cr |
| Investing Cash Flow | -201.08 Cr | 510.55 Cr | -67.83 Cr |
| Net Other Investing Changes | 4.40 Cr | 553.57 Cr | — |
| Interest Received Cfi | 13.23 Cr | 2.94 Cr | 3.03 Cr |
| Net Investment Purchase And Sale | -90.56 Cr | 21.59 Cr | -26.87 Cr |
| Purchase Of Investment | -90.56 Cr | -39.42 Cr | -26.87 Cr |
| Net Business Purchase And Sale | 0.00 | -3.79 Cr | 0.00 |
| Purchase Of Business | 0.00 | -3.79 Cr | 0.00 |
| Capital Expenditure Reported | -128.15 Cr | -63.77 Cr | -43.99 Cr |
| Operating Cash Flow | -67.85 Cr | -107.21 Cr | -162.76 Cr |
| Taxes Refund Paid | -7.01 Cr | 0.00 | 10.93 Cr |
| Change In Working Capital | -419.89 Cr | -4.13 Cr | 21.70 Cr |
| Change In Other Current Liabilities | -14.25 Cr | 89.45 Cr | 43.46 Cr |
| Change In Other Current Assets | -74.87 Cr | -25.67 Cr | 1.23 Cr |
| Change In Payable | -117.65 Cr | -16.09 Cr | 15.10 Cr |
| Change In Inventory | 43.99 Cr | -0.40 Cr | -57.90 Cr |
| Change In Receivables | -257.12 Cr | -51.42 Cr | 19.82 Cr |
| Other Non Cash Items | 150.41 Cr | 49.87 Cr | 116.83 Cr |
| Stock Based Compensation | 4.31 Cr | 1.96 Cr | 5.96 Cr |
| Provisionand Write Offof Assets | 0.69 Cr | 132.09 Cr | 200.22 Cr |
| Depreciation And Amortization | 273.88 Cr | 95.38 Cr | 114.10 Cr |
| Depreciation | 273.88 Cr | 95.38 Cr | 114.10 Cr |
| Gain Loss On Investment Securities | 0.23 Cr | 6.21 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -2.72 Cr | 2.50 Cr | 22.19 Cr |
| Net Income From Continuing Operations | -67.76 Cr | -391.17 Cr | -799.83 Cr |
| Short Term Debt Payments | — | -130.34 Cr | 0.00 |
| Sale Of Investment | — | 61.02 Cr | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on OneSource Specialty Pharma Inc
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.